Book contents
- The Movement Disorders Prescriber’s Guide to Parkinson’s Disease
- Reviews
- The Movement Disorders Prescriber’s Guide to Parkinson’s Disease
- Copyright page
- Contents
- Foreword
- Abbreviations
- Introduction
- Amantadine
- Amitriptyline
- Apomorphine Hydrochloride Subcutaneous Infusion
- Apomorphine Hydrochloride Subcutaneous Injection
- Apomorphine Hydrochloride Sublingual Film
- Botulinum Toxin
- Citalopram
- Clonazepam
- Clozapine
- Desipramine
- Domperidone
- Donepezil
- Droxidopa
- Entacapone
- Fludrocortisone
- Glycopyrrolate
- Istradefylline
- Levodopa–Benserazide
- Levodopa–Carbidopa
- Levodopa–Carbidopa Intestinal Gel
- Levodopa–Carbidopa–Entacapone Intestinal Gel
- Levodopa, Inhaled
- Lubiprostone
- Macrogol
- Melatonin
- Memantine
- Midodrine
- Mirabegron
- Mirtazapine
- Modafinil
- Naltrexone
- Nortriptyline
- Opicapone
- Oxybutynin
- Pimavanserin
- Piribedil
- Pramipexole*
- Quetiapine
- Rasagiline
- Rivastigmine
- Ropinirole
- Rotigotine
- Safinamide
- Selegiline
- Sildenafil
- Solifenacin
- Tolcapone
- Tolterodine
- Trihexyphenidyl
- Venlafaxine
- Zonisamide
- Levodopa Dose Equivalence in Parkinson’s
- Subcutaneous Foslevodopa Foscarbidopa infusion
- Index
- References
Modafinil
Published online by Cambridge University Press: 20 February 2025
Book contents
- The Movement Disorders Prescriber’s Guide to Parkinson’s Disease
- Reviews
- The Movement Disorders Prescriber’s Guide to Parkinson’s Disease
- Copyright page
- Contents
- Foreword
- Abbreviations
- Introduction
- Amantadine
- Amitriptyline
- Apomorphine Hydrochloride Subcutaneous Infusion
- Apomorphine Hydrochloride Subcutaneous Injection
- Apomorphine Hydrochloride Sublingual Film
- Botulinum Toxin
- Citalopram
- Clonazepam
- Clozapine
- Desipramine
- Domperidone
- Donepezil
- Droxidopa
- Entacapone
- Fludrocortisone
- Glycopyrrolate
- Istradefylline
- Levodopa–Benserazide
- Levodopa–Carbidopa
- Levodopa–Carbidopa Intestinal Gel
- Levodopa–Carbidopa–Entacapone Intestinal Gel
- Levodopa, Inhaled
- Lubiprostone
- Macrogol
- Melatonin
- Memantine
- Midodrine
- Mirabegron
- Mirtazapine
- Modafinil
- Naltrexone
- Nortriptyline
- Opicapone
- Oxybutynin
- Pimavanserin
- Piribedil
- Pramipexole*
- Quetiapine
- Rasagiline
- Rivastigmine
- Ropinirole
- Rotigotine
- Safinamide
- Selegiline
- Sildenafil
- Solifenacin
- Tolcapone
- Tolterodine
- Trihexyphenidyl
- Venlafaxine
- Zonisamide
- Levodopa Dose Equivalence in Parkinson’s
- Subcutaneous Foslevodopa Foscarbidopa infusion
- Index
- References
Summary
Modafinil (2-[(diphenylmethyl)sulfinyl]acetamide) is a white to off-white crystalline powder with a molecular weight of 273.4 and a molecular formula of C15H15NO2S.
- Type
- Chapter
- Information
- The Movement Disorders Prescriber's Guide to Parkinson's Disease , pp. 293 - 302Publisher: Cambridge University PressPrint publication year: 2025
References
Suggested Reading
Adler, CH, Caviness, JN, Hentz, JG, Lind, M, Tiede, J. Randomized trial of modafinil for treating subjective daytime sleepiness in patients with Parkinson’s disease. Mov Disord 2003; 18(3): 287–293.CrossRefGoogle ScholarPubMed
Högl, B, Saletu, M, Brandauer, E, Glatzl, S, Frauscher, B, Seppi, K, Ulmer, H, Wenning, G, Poewe, W. Modafinil for the treatment of daytime sleepiness in Parkinson’s disease: a double-blind, randomized, crossover, placebo-controlled polygraphic trial. Sleep, 2002; 25(8): 905–909.CrossRefGoogle ScholarPubMed
Lou, JS, Dimitrova, DM, Park, BS, Johnson, SC, Eaton, R, Arnold, G, Nutt, JG. Using modafinil to treat fatigue in Parkinson disease: a double-blind, placebo-controlled pilot study. Clin Neuropharmacol 2009; 32(6): 305–310.CrossRefGoogle ScholarPubMed
Ondo, WG, Fayle, R, Atassi, F, Jankovic, J. Modafinil for daytime somnolence in Parkinson’s disease: double blind, placebo controlled parallel trial. J Neurol, Neurosurg, Psychiatry 2005; 76(12): 1636.CrossRefGoogle ScholarPubMed
Rodrigues, TM, Castro Caldas, A, Ferreira, JJ. Pharmacological interventions for daytime sleepiness and sleep disorders in Parkinson’s disease: Systematic review and meta-analysis. Parkinsonism Relat Disord 2016; 27: 25–34.CrossRefGoogle ScholarPubMed
References
AHFS Drug information, 2012. Bethesda: American Society of Health-System Pharmacists. Accessed on 30 December 20 via www.medicinescomplete.com.Google Scholar
Joint Formulary Committee. British National Formulary (online). London: BMJ Group and Pharmaceutical Press. Accessed on 30 December 20 via www.medicinescomplete.com.Google Scholar
Modafinil. In: Brayfield, A (Ed.), Martindale: The Complete Drug Reference. London: The Royal Pharmaceutical Society of Great Britain. Accessed on 30 December 2022 via www.medicinescomplete.com.Google Scholar
Modafinil. In DRUGDEX® System (electronic version). Truven Health Analytics, Greenwood Village, Colorado, USA. Accessed on 30 December 2022 via www.micromedexsolutions.com.Google Scholar
Nieves, AV, Lang, AE. Treatment of excessive daytime sleepiness in patients with Parkinson’s disease with modafinil. Clin Neuropharmacol 2002; 25(2): 111–114.CrossRefGoogle ScholarPubMed
Robertson, P, Jr, Hellriegel, ET. Clinical pharmacokinetic profile of modafinil. Clin Pharmacokinet 2003; 42(2): 123–137.CrossRefGoogle ScholarPubMed
Summary of Product Characteristics – Modafinil 100 mg tablets. Aurobindo Pharma – Milpharm Ltd. Electronic Medicines Compendium: Modafinil 100 mg tablets – summary of product characteristics (SmPC) – (emc). Accessed on 30 December 2022 via www.medicines.org.uk.Google Scholar